نتایج جستجو برای: egfr mutation

تعداد نتایج: 315266  

2014
Xuefei Li Ruixin Ren Shengxiang Ren Xiaoxia Chen Weijing Cai Fei Zhou Yishi Zhang Chunxia Su Chao Zhao Jiayu Li Ningning Cheng Mingchuan Zhao Caicun Zhou

OBJECTIVE It is important to analyze and track Epidermal Growth Factor Receptor (EGFR) mutation status for predicting efficacy and monitoring resistance throughout EGFR-tyrosine kinase inhibitors (TKIs) treatment in non-small cell lung cancer (NSCLC) patients. The objective of this study was to determine the feasibility and predictive utility of EGFR mutation detection in peripheral blood. ME...

2013
Gerald S. M. A. Kerner Ed Schuuring Johanna Sietsma Thijo J. N. Hiltermann Remge M. Pieterman Gerard P. J. de Leede John W. G. van Putten Jeroen Liesker Tineke E. J. Renkema Peter van Hengel Inge Platteel Wim Timens Harry J. M. Groen

INTRODUCTION In randomly assigned studies with EGFR TKI only a minor proportion of patients with NSCLC have genetically profiled biopsies. Guidelines provide evidence to perform EGFR and KRAS mutation analysis in non-squamous NSCLC. We explored tumor biopsy quality offered for mutation testing, different mutations distribution, and outcome with EGFR TKI. PATIENT AND METHODS Clinical data from...

2013
Asao Sakai Kazuo Kasahara Takashi Sone

We report the case of a Japanese male with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)-sensitive lung adenocarcinoma, who had an EGFR mutation and presented in the emergency department with acute cardiac tamponade as the recurrence during EGFR-TKI therapy. We could detect a second mutation, T790M in exon 20 in the pericardial effusion. This is the first report to detec...

2016
Akash Verma Akhil Chopra Yeo W. Lee Lavina D. Bharwani Atasha B. Asmat Dokeu B.A Aneez Fazuludeen A. Akbar Albert Y.H. Lim Sanjay H. Chotirmall John Abisheganaden

BACKGROUND AND OBJECTIVE Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors (EGFR-TKIs) are effective against lung adenocarcinoma. However, limited data is available assessing the effectiveness of EGFR-TKI use in preventing re-accumulation of MPE. To our knowledge, there is no literature on comparison of talc pleurodesis with EGFR-TKIs alone on re-accumulation of MPE in Asian populatio...

2015
EIRINI PAPADOPOULOU NIKOLAOS TSOULOS ANGELIKI TSIRIGOTI ANGELA APESSOS KONSTANTINOS AGIANNITOPOULOS VASILIKI METAXA-MARIATOU KONSTANTINOS ZAROGOULIDIS PAVLOS ZAROGOULIDIS DIMITRIOS KASARAKIS STYLIANOS KAKOLYRIS JUBRAIL DAHABREH FOTIS VLASTOS CHARALAMPOS ZOUBLIOS AGGELIKI RAPTI NIKI GEORGATOU PAPAGEORGIOU DIMITRIOS VELDEKIS MINA GAGA GERASIMOS ARAVANTINOS VASILEIOS KARAVASILIS NAPOLEON KARAGIANNIDIS GEORGE NASIOULAS

It has been reported that certain patients with non-small-cell lung cancer (NSCLC) that harbor activating somatic mutations within the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene may be effectively treated using targeted therapy. The use of EGFR inhibitors in patient therapy has been demonstrated to improve response and survival rates; therefore, it was suggested ...

Journal: :Asian Pacific journal of cancer prevention : APJCP 2016
Juan Zhou Xing-Bo Song He He Yi Zhou Xiao-Jun Lu Bin-Wu Ying

AIMS To investigate the distribution of epidermal growth factor receptor (EGFR) mutations, and explore any relationships with clinical characteristics in non-small-cell lung carcinoma (NSCLC) patients. MATERIALS AND METHODS EGFR mutations were assessed by ADx-ARMS in 261 NSCLC patients from West China Hospital of Sichuan University. Relationships between EGFR mutation and clinical characteris...

2016
Shuhang Wang Stella T. Tsui Christina Liu Yongping Song Delong Liu

T790M mutation is the most common mechanism for resistance to first- and second-generation tyrosine kinase inhibitors (TKI) for epidermal growth factor receptor (EGFR). Several third-generation EGFR mutant selective TKIs are being explored to conquer this resistance. AZD9291 (osimertinib, tagrisso) has been approved for treatment of the metastatic EGFR T790M mutation-positive non-small cell lun...

2018
Wei-neng Feng Wei-quan Gu Ning Zhao Ying-ming Pan Wei Luo Hua Zhang Jian-miao Liang Jie Yang Yan-ming Deng

BACKGROUND Liquid biopsy is emerging as an important approach for tumor genotyping in non-small cell lung cancer, ddPCR and SuperARMS are both methods with high sensitivity and specificity for detecting EGFR mutation in plasma. We aimed to compare ddPCR and SuperARMS to detect plasma EGFR status in a cohort of advanced NSCLC patients. METHOD A total of 79 tumor tissues and paired plasma sampl...

Journal: :Cancer research 2000
L Frederick X Y Wang G Eley C D James

Several types of epidermal growth factor receptor (EGFR) gene mutations have been reported in glioblastomas, and in nearly all cases the alterations have been reported in tumors with EGFR amplification. The objectives of this study were to determine the frequency and diversity of EGFR mutations in glioblastomas and to determine whether gene mutation is inevitably associated with increased EGFR ...

Journal: :Bioscientia medicina 2022

Background. Mutation of the epidermal growth factor receptor (EGFR) in non-small cell lung carcinoma is a favorable predictive for targeted EGFR tyrosine kinase inhibitor (TKI) therapy, but patients with EGFR-mutated cancer who are given EGFR-TKI will experience disease progression after average 10 to 14 months on average. This study aims describe case progressive adenocarcinoma and its chemoth...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید